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Pathological angiogenesis and lymphangiogenesis are a hallmark
of cancer and both serve as the major routes for cancer cell
dissemination and metastasis. The tumor-vasculogenic process is
the result of the interaction between endothelial and tumor cells and
requires the coordinated actions of growth factors with both
angiogenic and lymphangiogenic properties. Unrevealing the poten-
tial mediators able to modulate this complex process would provide
the basis for the development of molecularly targeted therapeutics
directed against both tumor and tumor-associated endothelial cells.
The multifunctional peptide endothelin-1 (ET-1) and its receptors
have been correlated with invasiveness and metastasis and have
been shown to be markedly increased in the vasculature of several
kinds of tumors and associated with tumor grade and poor
prognosis. ET-1 acts in both blood and lymphatic endothelial as well
as in tumor cells through its G-protein coupled receptors, ETA and
ETB, to promote angiogenesis and lymphangiogenesis. The mecha-
nism by which ET-1 promotes these processes is beginning gradually
deﬁned. During tumor progression ET-1 exerts crucial roles in the
vasculogenic switch promoting, via ETBR, endothelial cell proliferation,
migration, protease production and morphogenesis, and, via both
receptors, vascular endothelial growth factor (VEGF) release.Moreover,
ET-1 stimulates highly aggressive tumor cells to form vessel-like
networks that do not involve endothelial cells. The ET-1-induced
vasculogenic effects, progress through the induction of the transcrip-
tional hypoxia-inducible factor (HIF)-1α and HIF-2α, and through a
complex interplaywith VEGF familymembers. Furthermore, expression
of ET-1 and its receptors is controlled by VEGF and hypoxia in both
endothelial and tumor cells, suggesting that a positive interegulation
between ET-1/HIF-1α, VEGF and hypoxia is able to amplify the
neovasculogenic response. The better mechanistic understanding of
these complex interactions is gradually paving the way toward the
rationale exploitation of the ET-1/ET receptor signaling pathway as a
therapeutically attractive target for neoplastic disease characterized by
active neovascularisation.
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Increased endothelin-1 decreases PKC alpha (PKCα), resulting
in high miRNA 15a levels in kidney tumors. Breast cancer cells
treated with ET-1, β-estrogen, Tamoxifen, Tamoxifen + β-estrogen
and Tamoxifen + ET-1 were analysed regarding miRNA 15a expres-
sion. Signiﬁcantly increased miRNA 15a levels were found after ET-1,
becoming further increased in Tamoxifen + ET-1 treated cells. Our
group already showed that miRNA 15a induces MAPK p38 splicing
resulting in a truncated product called Mxi-2, whose function has yet
to be deﬁned in tumors. We described for the ﬁrst time in ET-1
induced tumor cells that Mxi-2 builds a complex with Ago2, a miRNA
binding protein, which is important for the localization of miRNAs to
the 3′UTR of target genes. Furthermore, we show that Mxi-2/Ago2 is
important for the interactionwith themiRNA 1285which binds to the
3′end of the tumor suppressor gene p53, being responsible for the
downregulation of p53. Tissue arrays from breast cancer patientswere
performed, analysing Mxi-2, p53 and PKCα. Since the Mxi-2 levels
increase in Tamoxifen + ET-1 treated cells, we claim that increasing
ET-1 levels in Tamoxifen treated breast cancer patients are responsible
for decreasing p53 levels. In summary, ET-1 decreases nuclear PKCα
levels, while increasing the amount of miRNA 15a. This causes high
levels of Mxi-2, necessary for complex formation with Ago2. The newly
identiﬁed Mxi-2/Ago2 complex interacting with miRNA 1285 leads to
increased 3′UTR p53 interaction, resulting in decreased p53 levels and
subsequent tumor progression. This newly identiﬁed mechanism is a
possible explanation for the development of ET-1 induced tumors.
doi:10.1016/j.lfs.2013.12.041
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